Published on May 12, 2023
–
Updated on July 4, 2023
Dates
on the May 12, 2023
DiogenX raises €27.5 million to advance its regenerative diabetes treatment towards clinical development. The company, co-founded by Patrick Collombat, Inserm Senior Researcher at the Valrose Institute of Biology, specializes in the treatment of type 1 diabetes. DiogenX's flagship program could become the first disease-modifying treatment for symptomatic type 1 diabetes. This financing round, led by Boehringer Ingelheim Venture Fund and Roche Venture Fund, will fund the company's innovative approach to beta cell regeneration. DiogenX's flagship program could become the first disease-modifying treatment for symptomatic type 1 diabetes.
DiogenX is a biotechnology company specializing in the regeneration of insulin-producing beta cells for the treatment of diabetes.
Created in 2020 based on the research of Patrick Collombat, one of the leading scientists in the field of pancreatic beta cell regeneration, DiogenX develops first-in-class recombinant proteins designed for the treatment of type 1 diabetes. Patrick Collombat is Inserm Senior Researcher at the Valrose Institute of Biology, which hosts DiogenX's research activity.
DiogenX's flagship program focuses on modulating the Wnt/βcatenin signaling pathway to regenerate insulin-producing pancreatic beta cells to provide a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development.
DiogenX is supported by a network of global diabetes experts and a consortium of investors, including leading diabetes and biopharma companies
Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, Omnes, JDRF T1D Fund and Adbio partners.
The company, co-founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in Marseille.
Read DiogenX's press release
Created in 2020 based on the research of Patrick Collombat, one of the leading scientists in the field of pancreatic beta cell regeneration, DiogenX develops first-in-class recombinant proteins designed for the treatment of type 1 diabetes. Patrick Collombat is Inserm Senior Researcher at the Valrose Institute of Biology, which hosts DiogenX's research activity.
DiogenX's flagship program focuses on modulating the Wnt/βcatenin signaling pathway to regenerate insulin-producing pancreatic beta cells to provide a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development.
DiogenX is supported by a network of global diabetes experts and a consortium of investors, including leading diabetes and biopharma companies
Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, Omnes, JDRF T1D Fund and Adbio partners.
The company, co-founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in Marseille.
Read DiogenX's press release
